FDA stalls I.V. drug, asks to see more from Scynexis
By Randy Osborne
Staff Writer
Staff Writer
In a second-quarter meeting with the FDA, Scynexis Inc. will be talking about three mild to moderate thrombotic events in healthy phase I volunteers.
